Brokerages Set Emergent Biosolutions Inc. (NYSE:EBS) Price Target at $10.00

by · The Markets Daily

Emergent Biosolutions Inc. (NYSE:EBS – Get Free Report) has earned a consensus rating of “Hold” from the six analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $10.00.

EBS has been the topic of a number of analyst reports. Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. Benchmark reiterated a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Emergent Biosolutions in a research note on Wednesday, September 9th. Zacks Research upgraded Emergent Biosolutions to a “hold” rating in a report on Tuesday, August 11th. Finally, UBS Group reaffirmed a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd.

Check Out Our Latest Stock Analysis on EBS

Insider Buying and Selling

In other news, SVP Paul Williams sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the transaction, the senior vice president directly owned 159,098 shares in the company, valued at $1,336,423.20. This trade represents a 1.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Emergent Biosolutions

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Globeflex Capital L P acquired a new position in shares of Emergent Biosolutions during the second quarter valued at $2,022,000. BlackRock Inc. acquired a new stake in shares of Emergent Biosolutions in the second quarter valued at approximately $39,525,000. Pacer Advisors Inc. bought a new stake in shares of Emergent Biosolutions during the first quarter valued at approximately $3,454,000. Palisade Capital Management LP bought a new stake in shares of Emergent Biosolutions during the second quarter valued at approximately $4,316,000. Finally, Ancora Advisors LLC acquired a new position in shares of Emergent Biosolutions during the second quarter worth approximately $8,949,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Emergent Biosolutions Price Performance

Shares of NYSE:EBS opened at $6.36 on Thursday. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.95 and a current ratio of 5.42. The business’s fifty day moving average price is $6.42 and its two-hundred day moving average price is $7.69. The stock has a market cap of $325.87 million, a PE ratio of -1.79 and a beta of 2.34. Emergent Biosolutions has a one year low of $4.36 and a one year high of $14.06.

Emergent Biosolutions (NYSE:EBS – Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.68. The business had revenue of $234.30 million for the quarter, compared to the consensus estimate of $177.50 million. Emergent Biosolutions had a positive return on equity of 16.35% and a negative net margin of 22.95%. On average, analysts forecast that Emergent Biosolutions will post 0.13 EPS for the current fiscal year.

Emergent Biosolutions Company Profile

(Get Free Report)

Emergent BioSolutions Inc is a life sciences company focused on developing, manufacturing and supplying medical countermeasures and other products intended to address public health threats. Its activities include vaccines, therapeutics and treatments for infectious diseases, overdoses and other emergency health situations, as well as contract development and manufacturing services for pharmaceutical and biotechnology companies.

The company’s portfolio has included BioThrax, an anthrax vaccine, and ACAM2000, a smallpox vaccine supplied primarily for preparedness programs.

See Also